Comment on “The economics of follow-on drug research and development: Trends in entry rates and the timing of development” Aidan Hollis Commentary 17 September 2012 Pages: 1187 - 1192
The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply Joseph A. DiMasiCherie Paquette Commentary 17 September 2012 Pages: 1193 - 1202
No room for kinkiness in a public healthcare system Jack Dowie Commentary 17 September 2012 Pages: 1203 - 1205
Cost-effectiveness acceptability curves and a reluctance to lose Johan L. SeverensDaniëlle E. M. BrunenbergManuela A. Joore Leading Article 17 September 2012 Pages: 1207 - 1214
Willingness to pay for inhaled insulin Hamid SadriLinda D. MacKeiganThomas R. Einarson Original Research Article 17 September 2012 Pages: 1215 - 1227
Estimating mean total costs in the presence of censoring Tracey A. Young Original Research Article 17 September 2012 Pages: 1229 - 1242
A willingness-to-pay assessment of parents’ preference for shorter duration treatment of acute otitis media in children Delphine Gueylard ChenevierJacques LeLorier Original Research Article 17 September 2012 Pages: 1243 - 1255
Pramipexole and levodopa in early parkinson’s disease Katia NoyesAndrew W. DickRobert G. Holloway Original Research Article 17 September 2012 Pages: 1257 - 1270
Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease Colin GreenJoanna PicotAndrew Clegg Original Research Article 17 September 2012 Pages: 1271 - 1282
Rizatriptan Paul L. McCormackRachel H. Foster Adis Pharmacoeconomic Drug Evaluation 17 September 2012 Pages: 1283 - 1298